Tested. Trusted.
Market-leading drug-coated balloon

75% of patients treated with IN.PACT™ Admiral™ DCB remain reintervention-free at five years.1
Contact us
Alert Indications, Safety, and Warnings

Long-term outcomes

IN.PACT Admiral continues to demonstrate long-term clinical outcomes, even in patients considered to be at high risk of restenosis and repeat interventions.

Freedom from CD-TLR through five years:

  • 74.5% IN.PACT SFA Trial1
  • 58.0% IN.PACT Global ISR Cohort2
  • 67.3% IN.PACT Global Long Lesion Cohort2
  • 69.8% IN.PACT Global CTO Cohort2
IN.PACT Admiral trials

IN.PACT Admiral DCB has the:

  • Highest patency benefit through three years compared to PTA†1
  • Lowest CD-TLR rate through five years1
  • Most publications for a DCB‡

View the data

Proven formulation

The IN.PACT Admiral DCB features a proprietary FreePac™ coating solution that allows for the release of drug into the tissue through the restenotic window.

Duration of paclitaxel in tissue
IN.PACT Admiral DCB provides 180 days of drug in tissue.§3

Bar chart showing the number of days paclitaxel can be measured in tissue for IN.PACT Admiral, Lutonix, Ranger, and Stellarex
Download brochure
View product details

Impact on patient care

Watch Dr. Ehrin Armstrong speak about the benefits and clinical evidence to support IN.PACT Admiral as his DCB of choice.
More information (see more) Less information (see less)

Meet Robert Canterbury, who was diagnosed with peripheral artery disease (PAD), and see how IN.PACT Admiral DCB helped get him back on his feet.
More information (see more) Less information (see less)

Additional resources

Going the distance

See size options

Related resources

Connect with us

Reach a Medtronic sales rep
Contact us here

CardioVascular Lifeline
Customer Support
1-763-526-7890
rs.cstechsupport@medtronic.com

Orders
1-763-514-8510
rs.cuvasorders@medtronic.com

24-hour Technical Support
1-763-514-4000 (worldwide)

*

Third-party brands are trademarks of their respective owners.

†

Primary patency not assessed after three years.

‡

Publications on file with Medtronic.

§

Data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.

References

1

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.

2

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.

3

FDA. PMA P140010: Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140010. Accessed May 10, 2022.

4

FDA. PMA P190019: FDA Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190019. Accessed May 10, 2022.

5

Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. January 1, 2014;83(1):132-140.

6

FDA. PMA P160049: FDA summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160049. Accessed May 10, 2022.